Save over 55% with brand Name Lyparza from Europe and over 85% with generic versions of Lynparza.
Click here for information on Natco generics (immediate availability)
Non-english packaging is often present for European medicines- English label and English insert included. Plan in advance - allow us 7 days to ship this brand name medicine.
According to the European Medicines Agency, brand name xxx originating from Europe is manufactured at the following site(s):
AstraZeneca AB
Gärtunavägen
SE-152 57 Södertälje
Sweden
AstraZeneca UK Limited
Silk Road Business Park
Macclesfield, Cheshire, SK10 2NA
United Kingdom
Information about Lynparza (Olaparib)
Lynparza is a targeted cancer therapy known as a PARP (poly ADP-ribose polymerase) inhibitor. It is used in the treatment of certain types of cancers, particularly those associated with BRCA1 and BRCA2 gene mutations.
Product Highlights
- Inhibits PARP enzymes involved in DNA repair, leading to the accumulation of DNA damage in cancer cells and promoting cell death.
- Treatment for women with recurrent ovarian cancer associated with BRCA mutations.
- Used in certain patients with BRCA-mutated breast cancer.
- Also indicated for patients with specific genetic profiles in these cancers.
Key Ingredient
Key Benefits
- Specifically benefits patients with BRCA mutations, increasing treatment effectiveness.
- Convenient oral dosing allows for easier management at home.
- May extend progression-free survival in certain cancer types.
Direction of Use
- Typically, the recommended dose is 300 mg taken twice daily, but this may vary based on individual patient factors.
- Can be taken with or without food; patients should adhere to their healthcare provider's recommendations.
Safety Concerns
- May include nausea, fatigue, anemia, and increased risk of infections.
- Regular blood tests may be required to monitor for side effects, particularly blood counts.
Avoid Lynparza (Olaparib) If
- History of hypersensitivity to olaparib or any of its components.
- Caution is advised in patients with severe liver disease.
- Not recommended for use during pregnancy or while breastfeeding due to potential risks to the fetus or infant.
